jingwen yin

Director @ Harbour BioMed

About

Hi everyone, Thanks for viewing my profile. Here are my summarised skills. Let me know if you are interested and I would be to very happy to share with you a few interesting stories. • A strong background in synthetic biology, biomedical engineering (viruses, cells, DNA, and proteins), biochemistry, cell biology, virology, and fluorescence microscopy. • Get a challenging structure-based nanoantibody (VHH), or single chain antibody (scFv)-engineering project to work. • Expertise with molecular cloning techniques (enzyme digestion-ligation, Gibson assembly, In-fusion cloning, Gateway cloning, Slic cloning, Golden Gate cloning, QuickChange site directed mutagenesis). • Familiar with protein purification from E.coli and mammalian cells. • Expertise in the protein charaterization (native gel, SDS-PAGE, and western blot). • Expert with statistic data analysis (ex:Prism) and presentation (power point). • Excellent oral and written communication skills in english, multiple experiences of presentation in international conferences. • An innovator with track record in molecular design of biologics, of creative and proactive approach to problem solving, and strong analytical skills. • Strong track record of paper publications (6 first author papers) and one invention patent. • Love synthetic biology and biological engineering. • A team worker that enjoys communicating with people and eagers to learn new techniques. • R&D experience in the early lab-investigation stage of gene therapy company “Iconovir” (oncolytic adenovirus engineering, library establishment, and mid-high throughput cell-level screening). • Experienced in CRISPR, TALEN, PiggyBac gene editing. • Familiar with lentivirus, retrovirus, adenovirus, AAV production. • Skilled in studying protein-protein interaction (yeast two-hybrid, epitope-tagging/co-IP, endogenous protein/co-IP) and protein-DNA interactions (CHIP, CHIP-seq, EMSA). • Experiences in Next-generation sequencing (NGS) (RNA-seq, CHIP-seq).

Country

United States

City

San Diego

Industry

Research

Skill

Large scale adenovirus engineering and production, Confocal microscpy, Flow cell sorter, TECAN with robot, Cytation 5 imaging reader, Establishing disease mouse model (hypertension), Isolating primary cells from mouse tissue, Synthetic biology, CRISPR genome editing

Experience

Director

Harbour BioMed

2025-1 - Present · 1 yr 9 mos

Shanghai, China

• Lead projects from initiation to IND • Bi-specific or multi-specific antibody development using HCAb or H2L2 mice （Harbour mice） • Focus on autoimmune diseases

Sr. principal scientist I

Harbour BioMed

2022-1 - 2025-1 · 3 yrs 1 mo

Pudong, Shanghai, China

• New targets evaluation. Leading and push the progress of new projects. • Mono- or Bi-specific antibody drug development. • Develop myeloid, macrophage agonist/engager.

Sr. Postdoc

Salk Institute for Biological Studies

2020-3 - 2021-11 · 1 yr 9 mos

美国

• Engineered/developed a genetically-encoded nanoantibody-derived nanoparticle probes containing “targeting module+ functional module”. This probe can target proteins, DNA, or RNA in vivo and be used on fluorescence microscopy and electron microscopy, also potentially on Cryo-EMT, MRI, X-ray. This probe has multiple advantages over nanogold particle probes that are frequently used in EM imaging field. • R&D experiences in the establishment of a company (IconOVir) Contribute to design and establishing oncolytic adenovirus libraries and screen for synthetic adenoviruses that can specifically kill P53 or RB-negative cancer cells, or specifically target cancer sites in multiple cancel animal models, et al. • The work in the period resulted in one co-inventor patent and two first-author papers (in preparation).

Postdoc

Salk Institute for Biological Studies

2014-3 - 2020-3 · 6 yrs 1 mo

• Gene knock-out/knock-in by CRISPR 1) Generated P53 knock-out A549 cell line (lung cancer) to screen for candidate oncolytic adenoviruses with the potential to kill P53-negative cancer cells specifically. 2) Knock in tags (mCherry for fluorescence microscopy) to endogenous gene (PML) in U2OS cell lines (bone cancer) for understanding its function during adenovirus infection. 3) Knock in tags (minisog for FM and EM) to endogenous gene (PML) in U2OS cell lines (bone cancer) for visualizing the high-resolution structure of PML and virus protein. • Routinely generate stable cell lines through lentivirus, retrovirus, and PiggyBac. • Perform transient gene expression through adenovirus, AAV, electroporation, or transfection (Lipo, PEI, X-tremeGENE). • Next-generation sequencing for identifying downstream gene targets after infection of multiple synthesized oncolytic adenoviruses. • The work in the period resulted in one co-inventor patent

Chinese Academy of Sciences (Shanghai institute of biochemistry and cell biology)

Postdoc.

2012-3 - 2014-3 · 2 yrs 1 mo

• Developed disease-mouse models (hypertension) to understand the function of Med23 in disease development. The work were published in journals Cell Discovery and the EMBO journal.